[Form 4] Pacira BioSciences, Inc. Insider Trading Activity

Pacira BioSciences Chief Commercial Officer Brendan Teehan acquired additional company stock through an employee purchase plan.

Rhea-AI Filing Summary

Pacira BioSciences Chief Commercial Officer Brendan Teehan acquired additional company stock through an employee purchase plan. On 12/31/2025, he obtained 402.268 shares of Pacira common stock at a price of $10.763 per share under the issuer's employee stock purchase plan.

After this transaction, Teehan directly beneficially owned a total of 54,402.268 shares of Pacira common stock, reflecting his ongoing equity participation as an executive officer.

Insider Trade Summary

Grant/Award: 402.268 shares

Grant/Award 1 txn

Insider Teehan Brendan

Role Chief Commercial Officer

Type	Security	Shares	Price	Value
Grant/Award	Common Stock	402.268	$10.763	$4K

Holdings After Transaction: Common Stock — 54,402.268 shares (Direct)

Footnotes (1)

1. F1. Represents shares of common stock acquired under the issuer's employee stock purchase plan in December 2025.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did Pacira BioSciences (PCRX) report?

Pacira BioSciences reported that Chief Commercial Officer Brendan Teehan acquired 402.268 shares of common stock on 12/31/2025 through an employee stock purchase plan.

At what price were the Pacira (PCRX) shares acquired by the CCO?

The 402.268 shares of Pacira common stock were acquired at a price of $10.763 per share under the company’s employee stock purchase plan.

How many Pacira (PCRX) shares does Brendan Teehan own after this transaction?

Following the reported transaction, Chief Commercial Officer Brendan Teehan beneficially owned 54,402.268 shares of Pacira BioSciences common stock directly.

What is the source of the acquired Pacira (PCRX) shares in this Form 4?

The filing states that the shares represent common stock acquired under Pacira’s employee stock purchase plan in December 2025.

Is this Pacira (PCRX) Form 4 transaction direct or indirect ownership?

The Form 4 indicates that the reported 54,402.268 shares are held with direct ownership by Chief Commercial Officer Brendan Teehan.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 01/06/2026 - 05:30 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Teehan Brendan

(Last) (First) (Middle)

C/O PACIRA BIOSCIENCES, INC.

2000 SIERRA POINT PARKWAY, SUITE 900

(Street)

BRISBANE CA 94005

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Pacira BioSciences, Inc. [ PCRX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Commercial Officer

3. Date of Earliest Transaction (Month/Day/Year)
12/31/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	12/31/2025		A	V	402.268(1)	A	$10.763	54,402.268	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents shares of common stock acquired under the issuer's employee stock purchase plan in December 2025.

Remarks:

	/s/ Kristen Williams, Attorney-in-Fact	01/06/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.